[
  {
    "question": "What you can see with RCVS",
    "option_a": "Low glucose",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Reversible Cerebral Vasoconstriction Syndrome (RCVS) is characterized by sudden, severe (\u201cthunderclap\u201d) headaches and reversible segmental narrowing of cerebral arteries. Recognizing its typical imaging findings is crucial for diagnosis. RCVS reflects transient dysregulation of cerebrovascular tone, often triggered by vasoactive substances, the postpartum state, or certain medications. The fluctuating vasospasm produces a characteristic pattern of multifocal arterial narrowing that reverses over time. Patients with RCVS typically present with sudden-onset, severe headaches. Some may develop focal neurologic deficits or experience seizures. Importantly, imaging often reveals the hallmark multifocal and segmental narrowing of cerebral vessels. Diagnosis relies on neuroimaging. Magnetic resonance angiography (MRA), computed tomography angiography (CTA), or digital subtraction angiography (DSA) typically reveal a \u2018string-of-beads\u2019 appearance due to alternating constriction and dilation. Differential diagnoses include aneurysmal subarachnoid hemorrhage, primary angiitis of the central nervous system, and cerebral vasculitis. Management is predominantly supportive. First\u2010line treatment includes removal of any offending agents and symptomatic management. Calcium channel blockers (such as nimodipine or verapamil) may be used to alleviate vasoconstriction. In pregnant or lactating patients, careful drug selection is essential; for example, although many calcium channel blockers are category C, they may be used if the benefits outweigh the potential risks. Option A (Low glucose) is not a feature of RCVS and does not reflect the underlying vascular abnormality. Although the other options were not explicitly provided, the correct answer should highlight the reversible vasoconstrictive changes seen on imaging \u2013 corresponding to Option B. 1. RCVS is most commonly identified by its thunderclap headache and reversible, multifocal segmental vasoconstriction on angiographic studies. 2. It is important not to confuse RCVS with primary vasculitis, as the treatment strategies differ markedly. Recent research emphasizes early and accurate imaging to differentiate RCVS from other cerebral vasculopathies. Updated guidelines advocate for supportive management with avoidance of triggers, reinforcing that abnormal glucose levels are not a feature of this condition.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "60 years old male pt DM/ HTN/ came with history of TiA for 10 min numbness and dysarthtia. NiHSs is 3. We have to calculate ABCD2 score. On examination ot still have numbness what you will give",
    "option_a": "aspirin",
    "option_b": "plavix",
    "option_c": "dual",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "The ABCD2 score is a clinical tool for risk-stratifying patients after a transient ischemic attack (TIA) to predict the short-term risk of stroke. It incorporates Age, Blood pressure, Clinical features, Duration of symptoms, and Diabetes. TIAs result from transient cerebral ischemia, often due to embolism or small vessel occlusion in the setting of underlying atherosclerosis. The score reflects the cumulative risk imposed by these factors. In a 60\u2010year\u2010old male with traditional vascular risk factors and a transient episode of neurological deficits, a high ABCD2 score indicates a substantial risk for future stroke. Persistent neurologic deficits (such as ongoing numbness) further raise concern and influence treatment intensity. Differentiation involves excluding mimics like migraine, seizure-related symptoms, or hypoglycemia. Neuroimaging (CT/MRI) is needed to rule out acute infarction and to evaluate for underlying vascular pathology. Current guidelines, informed by trials such as CHANCE and POINT, support the initiation of dual antiplatelet therapy (aspirin plus clopidogrel) within 24 hours of a high-risk TIA or minor stroke and continuing it for 21\u201390 days before transitioning to monotherapy. Although this patient is a 60-year-old male, these principles are standard; in pregnant or lactating patients, low-dose aspirin is often acceptable, but clopidogrel has a less established safety profile and is generally used with caution. Option A (aspirin alone) and Option B (clopidogrel alone) may be considered in lower-risk settings, but for high-risk TIA, dual therapy (Option C) has been proven superior in reducing early recurrent stroke risk. Option D was not provided. 1. Dual antiplatelet therapy is beneficial when initiated early in high-risk TIA or minor stroke patients to reduce recurrent stroke risk. 2. The ABCD2 score is an essential clinical tool for determining the intensity of secondary prevention strategies. Large-scale trials, including CHANCE and POINT, have firmly established the benefit of dual antiplatelet therapy in reducing stroke recurrence in patients with high ABCD2 scores, thereby shaping current guideline recommendations.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What you will do:",
    "option_a": "(angioplasty alone) is not recommended because it can lead to vessel recoil and restenosis. Option B (stenting) is typically reserved for patients who cannot undergo surgery, while Option C (endarterectomy) is an option for selected high",
    "option_b": "",
    "option_c": "",
    "option_d": "(medical therapy) is the most appropriate initial approach in a broad range of patients with large vessel stenosis.",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Management of symptomatic large vessel cerebrovascular stenosis requires an evaluation of both the severity of the stenosis and the symptoms. The initial treatment approach generally prioritizes optimized medical management over immediate invasive procedures. Atherosclerotic disease in large vessels, such as the carotid arteries, leads to narrowing and turbulent flow that predisposes to thromboembolic events and hypoperfusion. The chronic inflammatory process leads to plaque formation and progression of stenosis. Patients with symptomatic stenosis presenting with TIA or minor stroke symptoms are at risk for further ischemic events. While invasive procedures like endarterectomy or stenting can reduce stroke risk in selected patients, many individuals initially benefit from aggressive medical therapy that addresses risk factors and stabilizes plaque. Diagnosis is typically confirmed by noninvasive imaging modalities such as carotid duplex ultrasonography, CTA, or MRA. Differential diagnoses include intracranial atherosclerosis, vasculitis, and cardioembolic sources; the degree of stenosis guides the treatment plan. Current guidelines emphasize that the first-line management for most patients with large vessel stenosis is optimized medical therapy. This includes antiplatelet agents (often aspirin \u00b1 clopidogrel), high-intensity statin therapy, strict blood pressure control, and lifestyle modification. In patients with high-grade (typically >70%) symptomatic stenosis, carotid endarterectomy (CEA) may be indicated if the patient is an appropriate surgical candidate. Carotid stenting is reserved for patients with contraindications to surgery. In pregnant and lactating patients, medications must be selected for safety; for example, low-dose aspirin is generally acceptable in pregnancy, whereas many statins and interventional procedures are contraindicated or require special consideration. Option A (angioplasty alone) is not recommended because it can lead to vessel recoil and restenosis. Option B (stenting) is typically reserved for patients who cannot undergo surgery, while Option C (endarterectomy) is an option for selected high-grade stenosis cases but is not universally required. Option D (medical therapy) is the most appropriate initial approach in a broad range of patients with large vessel stenosis. 1. Optimal medical management, including risk factor modification, is the cornerstone of treatment for cerebrovascular stenosis. 2. Invasive interventions should be reserved for carefully selected patients after a thorough evaluation of stenosis severity. Recent trials such as SAMMPRIS and CREST have underscored the efficacy of aggressive medical therapy in reducing recurrent stroke risk and have helped refine the indications for interventional procedures in patients with large vessel cerebrovascular disease.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "sickler pt come with stroke work up done and found to have multiple stenosis in AcA and McA. Ehat is the method of prevention?",
    "option_a": "aspirin",
    "option_b": "plavix",
    "option_c": "chronic transfusion",
    "option_d": "dual antiplate",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In patients with sickle cell disease (SCD), the abnormal hemoglobin leads to red blood cell sickling, which can cause vaso-occlusion and vascular injury, notably in cerebral vessels. This predisposes them to stroke and progressive vasculopathy. The sickling of red blood cells in SCD results in chronic hemolysis and microvascular occlusions. Repeated vaso-occlusive events damage the endothelium, leading to intimal hyperplasia and progressive arterial stenosis, particularly affecting major intracranial arteries such as the anterior (AcA) and middle cerebral arteries (McA). SCD patients are at high risk for both overt and silent strokes, often presenting with transient ischemic attacks or neurological deficits. The identification of multiple intracranial stenoses on stroke workup is a common finding in this population. The evaluation involves neuroimaging studies, including MRA or CTA, to assess vessel patency and differentiate SCD vasculopathy from other conditions such as atherosclerotic disease or inflammatory vasculitis. Differential diagnoses include moyamoya syndrome and other forms of vasculitis. Chronic blood transfusion therapy is the cornerstone of both primary and secondary stroke prevention in SCD. Regular transfusions work by reducing the proportion of hemoglobin S below 30%, thereby minimizing sickling events and reducing stroke risk. Hydroxyurea may be considered as an adjunct therapy in some cases. In pregnant or lactating patients with SCD, transfusion protocols must be carefully managed by a multidisciplinary team, balancing maternal and fetal risks while ensuring optimal reduction in stroke risk. Option A (aspirin) and Option B (clopidogrel) are antiplatelet regimens typically used in atherosclerotic stroke prevention and do not address the underlying pathophysiology of SCD. Option D (dual antiplatelet therapy) similarly fails to alter the sickling process. Option C (chronic transfusion) is the established and effective method for stroke prevention in SCD by reducing the hemoglobin S load. 1. Chronic transfusion therapy remains the standard of care for stroke prevention in SCD, targeting a reduction in hemoglobin S levels. 2. SCD vasculopathy involves unique mechanisms distinct from atherosclerotic disease, thus requiring different treatment strategies. Recent studies continue to support the efficacy of chronic transfusion protocols in reducing stroke incidence in SCD patients. Ongoing research into adjunctive therapies, including hydroxyurea and gene therapy, aims to further improve outcomes in this high-risk population.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What is the mechanism?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question focuses on the mechanism underlying a specific subtype of subarachnoid hemorrhage (SAH) \u2013 the premesencephalic hemorrhage. Unlike the more common aneurysmal SAH, premesencephalic hemorrhage is a nonaneurysmal bleed localized to the pre\u2010mesencephalic cisterns. Premesencephalic hemorrhage is thought to arise from a venous or minor arterial source rather than from a ruptured aneurysm. Its bleeding is confined to the cisterns anterior to the midbrain with no aneurysm detected on vascular imaging. This distinct mechanism accounts for its generally benign clinical course compared with the typical aneurysmal bleed. Clinically, patients with a premesencephalic hemorrhage usually present with a less severe headache with fewer neurological deficits and have a lower risk of complications such as re-bleeding or vasospasm. Radiographically, the hemorrhage is localized, and CT angiography fails to reveal an aneurysm. The evaluation begins with a noncontrast head CT to confirm SAH. Given the hemorrhage\u2019s characteristic location, a CT angiogram (CTA) is used to exclude aneurysmal causes. In ambiguous cases, lumbar puncture may be performed. Differential diagnoses include aneurysmal SAH, perimesencephalic hemorrhage from other causes, and other intracranial hemorrhages. Management is mainly supportive. Patients are observed and managed conservatively with pain control and blood pressure regulation since there is no aneurysm to secure. In patients with this hemorrhage, aggressive interventions such as surgical clipping or coiling are not warranted. During pregnancy and lactation, conservative management remains the mainstay while monitoring maternal and fetal status. Option 1 (Aneurysm rupture) is incorrect because, while it is the most common cause of SAH, it does not account for the localized bleeding pattern and benign course of premesencephalic hemorrhage. Option 2 (Atherosclerosis) is not a cause of SAH but is linked to ischemic events. Option 3 (Premesencephalic hemorrhage) is the correct mechanism as it specifically describes the nonaneurysmal bleed observed in this scenario. Option 4 is not provided. 1. Premesencephalic SAH has a better prognosis than aneurysmal SAH. 2. Its characteristic CT findings (localized anterior to the midbrain) help differentiate it from aneurysmal SAH. 3. CTA is essential to rule out an aneurysm before determining conservative management. Recent studies support that in cases of SAH with a premesencephalic pattern and no vascular lesions on CTA, conservative management yields favorable outcomes. Advances in imaging continue to improve our ability to distinguish between aneurysmal and nonaneurysmal causes, thereby optimizing patient management.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "82 years old male pt came within 3 hrs and have no contraindication for tpa and ct attached with early signe of stroke but infarction not established what you will give",
    "option_a": "aspirin",
    "option_b": "plavix",
    "option_c": "tpa",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question addresses the acute management of ischemic stroke in the hyperacute phase. The mainstay treatment for eligible patients is thrombolysis with tissue plasminogen activator (tPA). In ischemic stroke, clot formation leads to occlusion of cerebral blood vessels, resulting in neuronal ischemia and infarction. Early restoration of blood flow with tPA can dissolve the thrombus, limiting tissue damage and improving outcomes. The patient, an 82\u2010year\u2010old male, presented within 3 hours of symptom onset with early signs on CT but without established infarction. The absence of contraindications combined with the timely presentation makes him a good candidate for tPA despite advanced age. Initial evaluation includes a noncontrast head CT to rule out hemorrhage, assessment of stroke symptoms, and careful review of contraindications. Differential diagnoses include stroke mimics such as seizures or hypoglycemia. However, early ischemic changes assessed on CT support the diagnosis of acute ischemic stroke. The current guidelines recommend intravenous tPA as a first-line treatment for eligible patients presenting within 3 hours (and in select cases up to 4.5 hours) of stroke onset. In elderly patients, tPA is not contraindicated; careful evaluation of bleeding risk is crucial. In pregnancy and lactation, tPA can be used if benefits outweigh risks, though data in these populations are limited and management should be individualized. Option A (Aspirin) and Option B (Plavix) are antiplatelet agents generally used for secondary prevention, not for acute reperfusion. Option C (tPA) is the correct choice as it is the established treatment in the hyperacute period when no contraindications exist. Option D is not provided. 1. Time is brain: early administration of tPA is critical. 2. Advanced age alone is not a contraindication for tPA. 3. CT imaging is essential to rule out hemorrhage before initiating therapy. Recent AHA/ASA updates affirm the benefit of tPA in eligible patients within the 3-hour window, with growing evidence supporting its use in patients over 80 years old, provided contraindications are absent. Ongoing research continues to refine selection criteria, including the use of advanced imaging techniques.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "pt suddenly explaned to his wife seeing animals and fade after while pt loss consciousness / EMd arrived. Take him to the hospital intubation done. Attache Ct scan. New left occipital stroke. What you will do? Pt presneted with window not mention bt writeen sudden and within 1 hr",
    "option_a": "cta",
    "option_b": "EEG",
    "option_c": "tpa",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question involves the acute management of an ischemic stroke presenting with occipital lobe involvement, where symptoms may include visual disturbances such as seeing animals (visual hallucinations). An infarct in the occipital lobe affects the visual processing center of the brain, leading to phenomena such as visual hallucinations or altered vision. This ischemic process results from an arterial occlusion that, if treated promptly, can be salvaged using reperfusion therapy. The case describes a patient with a new left occipital stroke who presented acutely (within 1 hour), making him an ideal candidate for thrombolytic therapy. Despite being intubated, if there are no contraindications and the patient is within the therapeutic window, tPA can significantly improve outcomes. A noncontrast CT scan is performed first to exclude hemorrhage, supported by clinical history. Although additional studies like CT angiogram (CTA) can help visualize vessel occlusion, the immediate determination of eligibility for tPA is paramount. Differential diagnosis would include seizure activity or other visual disturbances, but imaging confirming a new infarct solidifies the diagnosis. For eligible patients presenting within the approved time window (up to 4.5 hours, with the greatest benefit seen earlier), IV tPA is recommended as first-line therapy. The decision remains similar even in patients who have been intubated, provided airway management and supportive care are ensured. In pregnancy and lactation, treatment with tPA is considered on a case-by-case basis, weighing risks and benefits, though available data remain limited. Option A (CTA) is an imaging modality that can further evaluate vessel occlusion but is not a treatment. Option B (EEG) is unrelated and used to assess for seizures. Option C (tPA) is the appropriate therapeutic intervention to achieve reperfusion in an acute ischemic stroke. Option D is not provided. 1. Occipital strokes may present with visual hallucinations or disturbances. 2. Rapid identification and treatment with tPA are critical within the treatment window. 3. Intubation should not automatically preclude the use of tPA if other criteria are met. Current guidelines from the AHA/ASA strongly support the use of tPA in patients with acute ischemic stroke presenting within the therapeutic window. Research continues into optimizing patient selection using advanced imaging techniques to extend reperfusion therapy to more patients.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What yoi will do?",
    "option_a": "Shunt",
    "option_b": "anticoagulant",
    "option_c": "give",
    "option_d": "give LMWH",
    "option_e": "",
    "correct_answer": "Insufficient information to determine the correct management option",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question appears to ask for the next step in management, but the lack of clinical context (such as the underlying diagnosis or situation) makes it ambiguous. The provided options range from a surgical intervention (shunt), general anticoagulation, an unspecified 'give', or the use of low molecular weight heparin (LMWH). Without a clear clinical scenario, it is not possible to ascertain the underlying pathophysiological process. For instance, a shunt would be used for managing hydrocephalus, whereas LMWH is typically used for thromboembolic prophylaxis or treatment, and the generic term 'anticoagulant' could apply to multiple vascular conditions. The options suggest two distinct clinical pathways: one related to neurosurgical management (shunt placement for hydrocephalus) and the other related to medical management (anticoagulation or LMWH for thromboembolism or stroke prophylaxis). Without additional patient history, imaging details, or a specific diagnosis, correlating these options to a clinical presentation is not feasible. A proper diagnostic workup would require detailed history, physical examination, and appropriate imaging studies to differentiate between conditions such as normal-pressure hydrocephalus, cerebral venous thrombosis, or post-stroke deep venous thrombosis prophylaxis. Differential diagnoses might include hydrocephalus, acute ischemic stroke with subsequent thrombosis risk, or another cerebrovascular abnormality. Management should be tailored based on the definitive diagnosis. If the issue were hydrocephalus, a shunt procedure (typically a ventriculoperitoneal shunt) would be indicated. Conversely, if the patient has a thromboembolic disorder (such as cerebral venous thrombosis or requires DVT prophylaxis post-stroke), the use of anticoagulants like LMWH is appropriate. In pregnancy and lactation, LMWH is preferred over other anticoagulants because it does not cross the placenta and has a favorable safety profile during breastfeeding. Option A (Shunt) is correct if the underlying problem is hydrocephalus but irrelevant if the condition is thromboembolic in nature. Option B (anticoagulant) is a broad term and might be applicable in multiple scenarios but is non-specific. Option C (give) is incomplete and provides no actionable information. Option D (give LMWH) is appropriate for thromboembolic conditions (e.g., for prophylaxis in immobilized patients or in the treatment of cerebral venous thrombosis) as well as for VTE prevention in high-risk patients, including those who are pregnant or lactating. However, without further context, it is impossible to choose definitively among these. 1. Always ensure that a question provides adequate clinical context before selecting a management option. 2. In cases of cerebrospinal fluid buildup (hydrocephalus), a shunt is indicated, while in thromboembolic conditions, anticoagulation (preferably LMWH in pregnancy/lactation) is preferred. Recent guidelines underscore the importance of tailoring stroke and hydrocephalus management to the individual patient based on imaging and clinical presentation. In conditions requiring anticoagulation, LMWH remains the agent of choice in pregnant and lactating women due to its safety profile. However, current evidence also highlights the necessity of a precise diagnosis before initiating treatment.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Long senario pt came with anyrism rupture of PcOm what you will do?",
    "option_a": "Cliping",
    "option_b": "Coiling",
    "option_c": "Decompressivw craniotomy",
    "option_d": "Amdission to stroke unit",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Ruptured cerebral aneurysms, particularly those in the region of the posterior communicating artery (PCOM), lead to subarachnoid hemorrhage. The core concept is that rapid hemorrhage into the subarachnoid space may cause sudden, severe headache (often described as thunderclap headache) and neurological deficits, necessitating prompt intervention to secure the aneurysm and prevent re-bleeding. Aneurysms form due to the weakening of the arterial wall and, when ruptured, cause bleeding into the subarachnoid space. This generates a rise in intracranial pressure, risk of cerebral vasospasm, and ischemic injury to surrounding brain tissue. PCOM aneurysms are common and sometimes manifest with third nerve palsy due to proximity to the oculomotor nerve. Patients commonly present with a sudden, severe headache, nausea, vomiting, and sometimes loss of consciousness. Specific to PCOM aneurysms, unilateral oculomotor nerve palsy with ptosis and a dilated pupil may be observed due to the compressive effects of an enlarging aneurysm or hemorrhage. The initial diagnosis is typically made using a noncontrast CT scan to detect subarachnoid blood. This is followed by CT-angiography or digital subtraction angiography (DSA) to localize the aneurysm. Differential diagnoses include perimesencephalic subarachnoid hemorrhage and hypertensive hemorrhage, which can be differentiated by the bleeding pattern and location. Early securing of the aneurysm is the priority. Current guidelines suggest that endovascular coiling is preferred in many cases due to less invasiveness and favorable outcomes (as shown by the ISAT trial) if the aneurysm\u2019s anatomy is amenable. Surgical clipping remains an alternative if endovascular coiling is not feasible. Post-procedure, patients require management of vasospasm (typically with nimodipine), control of intracranial pressure, and supportive care. In pregnant patients, special considerations include minimizing radiation exposure (with appropriate shielding) and careful monitoring of fetal status during any interventional procedure, whereas during lactation, most contrast agents and anesthesia drugs are considered relatively safe with proper guidance. Option A (Clipping) is an acceptable treatment alternative but is generally reserved for aneurysms with unfavorable coiling anatomy. Option B (Coiling), the marked answer, is preferred in many centers for PCOM aneurysms due to lower procedural morbidity. Option C (Decompressive craniotomy) is not a direct treatment for an aneurysm rupture but may be used later in cases with malignant edema. Option D (Admission to stroke unit) is inadequate as definitive management and does not secure the aneurysm. 1. PCOM aneurysms can present with cranial nerve III palsy. 2. Early intervention is crucial to prevent re-bleeding and vasospasm. 3. Endovascular coiling offers a less invasive option with favorable outcomes in selected patients. Recent guidelines and trials (such as ISAT) support the use of endovascular coiling in appropriate aneurysms due to reduced morbidity and similar long-term outcomes to clipping. Ongoing research is focused on further refining patient selection and improving endovascular techniques.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Male 56 years old male pt found in teh house with decreas level of consuos Last tome seen normal 1 day back Brain ct scan showed:",
    "option_a": "tpa",
    "option_b": "admission to stroke unite",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "The management of stroke patients depends critically on the timing from symptom onset. In this scenario, a 56\u2010year\u2010old man was found with decreased consciousness and a known last normal time of 24 hours ago, which is well beyond the therapeutic window for thrombolytic therapy. Ischemic strokes are caused by occlusion of cerebral arteries leading to ischemia and infarction of brain tissue. The prolonged occlusion results in neuronal death and can cause significant deficits. The diminished level of consciousness could be from a large stroke or associated edema. Patients with ischemic stroke may present with various focal neurological deficits. A decreased level of consciousness in an elderly patient along with imaging findings on CT (even if not detailed here) necessitates prompt evaluation, though reperfusion therapies are time-sensitive. A noncontrast CT scan is generally performed to rule out hemorrhage. In patients presenting beyond the thrombolytic window, advanced imaging modalities like CT perfusion or MRI may be used in select cases to assess salvageable brain tissue. Differentials include hemorrhagic stroke, hypoglycemia, and seizure post-ictal states. Given that the patient is outside the therapeutic window for tPA (typically within 3-4.5 hours from onset), the current evidence supports admission to a dedicated stroke unit where specialized care, supportive management, and secondary prevention strategies are initiated. For pregnant patients with stroke, management must balance maternal benefits against fetal safety, with careful use of imaging and medications. For lactating mothers, medication choices are adjusted based on excretion in breast milk. Option A (tPA) is contraindicated due to the elapsed time since last known well. Option B (Admission to stroke unit) is appropriate and correct as specialized stroke care can improve outcomes. Options C and D are not provided or applicable in this context. 1. 'Time is brain' \u2013 rapid recognition and treatment are essential in stroke. 2. Patients discovered beyond the tPA window should be managed in a stroke unit to optimize supportive care and secondary prevention. 3. Advanced imaging may extend treatment windows in select patients but 24 hours is generally too long for standard tPA protocols. Recent studies confirm that dedicated stroke unit care consistently improves survival and functional outcomes. Although advanced imaging techniques have allowed for extended therapy windows in some cases (e.g., DAWN and DEFUSE 3 trials), these are typically limited to carefully selected patients within 24 hours and not applicable in a general scenario as described here.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_9.png"
  },
  {
    "question": "What is the artey?",
    "option_a": "mca",
    "option_b": "pca",
    "option_c": "ant choroidal artery",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question focuses on identifying the cerebral artery involved based on a presumed clinical or radiological scenario. The Middle Cerebral Artery (MCA) is the most commonly affected artery in ischemic strokes due to its direct flow from the internal carotid artery and its large territory of perfusion. Occlusion of the MCA typically leads to infarction in the regions of the brain it supplies. This results from thromboembolism or atherosclerotic narrowing. The large territory of the MCA means that occlusions often produce significant neurological deficits. Clinically, an MCA stroke often manifests with contralateral weakness (especially affecting the face and arm), sensory deficits, and if the dominant hemisphere is involved, aphasia. Visual field deficits may also occur if the inferior division is involved. Initial imaging with a noncontrast CT scan is used to exclude hemorrhage. MRI with diffusion-weighted imaging and CT angiography are instrumental in confirming an MCA occlusion and assessing the extent of core infarction versus salvageable penumbra. Differentials would include PCA infarction (which typically affects the occipital lobe and causes visual deficits) and anterior choroidal artery infarction (which often produces lacunar syndromes). If within the window, management of an MCA occlusion may include intravenous thrombolysis and/or mechanical thrombectomy for large vessel occlusions. Guidelines emphasize rapid reperfusion therapy and supportive care. For pregnant patients, thrombolysis may be considered on a case-by-case basis with proper precautions. In lactation, most agents used in stroke care have been evaluated for safety, though individual risk assessments are needed. Option A (MCA) is the correct answer, as it is the most common site for ischemic strokes and fits the described scenario. Option B (PCA) supplies the occipital lobe and is less commonly involved in the typical clinical presentation presented. Option C (Anterior choroidal artery) supplies deep brain structures and would usually produce a more restricted clinical syndrome. Option D is not provided. 1. The middle cerebral artery is the most commonly occluded vessel in ischemic stroke. 2. MCA territory infarcts are typically characterized by contralateral hemiparesis and aphasia if the dominant hemisphere is affected. 3. Quick identification and treatment are essential to improve outcomes. Recent guidelines emphasize the role of endovascular thrombectomy in MCA occlusions, particularly in large vessel occlusions, with multiple randomized controlled trials confirming its efficacy in improving functional outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "What is the mechanism?",
    "option_a": "tramatic haemorrage",
    "option_b": "ICh",
    "option_c": "lobar haemorrage",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question evaluates the understanding of the underlying mechanisms leading to intracranial bleeding. The differentiation between traumatic and spontaneous hemorrhages is critical in neurology. Here, the focus is on spontaneous intracerebral hemorrhage (ICH). Intracerebral hemorrhage typically occurs due to rupture of small penetrating arteries, most commonly as a consequence of chronic hypertension. Long-standing high blood pressure leads to changes in the vessel wall (e.g., formation of Charcot-Bouchard microaneurysms) which predispose them to rupture. Lobar hemorrhages, while a subset of ICH, are often associated with cerebral amyloid angiopathy, particularly in older patients. ICH presents with the sudden onset of headache, vomiting, a decline in levels of consciousness, and focal neurological deficits. The location of the hemorrhage (deep vs. lobar) can provide clues to its etiology; hypertensive ICH frequently occurs in deep structures such as the basal ganglia or thalamus. A noncontrast CT scan is the diagnostic modality of choice for ICH, as it quickly differentiates hemorrhagic from ischemic strokes. MRI can be used in subacute settings for further characterization. Differential diagnoses include traumatic brain hemorrhage, subarachnoid hemorrhage, and lobar hemorrhage due to different etiologies such as amyloid angiopathy. Management of ICH includes rapid blood pressure control, reversal of any coagulopathy, and supportive care. Patients may require neurosurgical evaluation for hematoma evacuation if there is significant mass effect or deterioration in the neurological exam. In pregnant patients, blood pressure control must consider both maternal and fetal safety, with agents chosen that have established safety profiles. In lactating mothers, medication choices are similarly guided by safety data for breastfeeding. Option A (Traumatic hemorrhage) is incorrect in the absence of a history of trauma. Option B (ICH) is the correct answer, representing a spontaneous intracerebral hemorrhage, likely hypertensive in origin. Option C (Lobar hemorrhage) is a subtype of ICH but typically relates to cerebral amyloid angiopathy in the elderly and is less likely in a 56-year-old man; thus, it is less appropriate without specific supporting details. Option D is not provided. 1. Hypertension is the most common risk factor for spontaneous ICH. 2. Blood pressure management is crucial in the acute phase to prevent hemorrhage expansion. 3. Differentiating the hemorrhage location (deep vs. lobar) assists in identifying the underlying etiology. Emerging research focuses on optimal blood pressure targets and minimally invasive surgical techniques for ICH evacuation. Current guidelines recommend early aggressive management of blood pressure and individualized decisions regarding surgical intervention, with ongoing studies further refining best practices.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Intracranial MCA severe stenosis what next",
    "option_a": "(DAPT) is correct because the SAMMPRIS trial demonstrated that using both aspirin and clopidogrel reduces recurrent stroke risk in severe intracranial stenosis. Other alternatives like single antiplatelet therapy, anticoagulation, or immediate endovascular procedures have either not shown superior benefits or carry higher procedural risks.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case involves a patient with severe intracranial stenosis of the MCA, a high\u2010risk condition for recurrent ischemic events. The aim is to stabilize the atherosclerotic plaque and prevent embolization, making antiplatelet therapy the mainstay of management. Severe intracranial stenosis is most commonly due to atherosclerotic disease. The culprit lesion leads to endothelial injury and turbulent blood flow, promoting platelet activation and microembolization. Dual antiplatelet therapy (DAPT)\u2014combining aspirin\u2019s irreversible COX inhibition with clopidogrel\u2019s blockade of the ADP receptor\u2014addresses two different pathways in platelet aggregation, as demonstrated in the SAMMPRIS trial. Clinically, patients might present with transient ischemic attacks or strokes confined to the vascular territory supplied by the affected MCA. The risk of subsequent stroke is high if the stenosis remains untreated, which makes early aggressive management essential. Imaging modalities like CTA, MRA, or digital subtraction angiography (DSA) are used to confirm the degree of stenosis. Differential diagnoses include extracranial carotid stenosis, vasculitis, or other intracranial arteriopathies. Noninvasive vascular imaging usually helps differentiate these conditions. According to current guidelines and the SAMMPRIS trial, the first-line management for symptomatic severe intracranial stenosis is aggressive medical therapy. DAPT (aspirin plus clopidogrel) should be initiated\u2014commonly for 90 days\u2014along with risk factor modification (blood pressure, lipids, glycemic control). Endovascular options (such as stenting) are reserved for cases refractory to medical management. In pregnancy or lactation, low-dose aspirin may be used safely; however, clopidogrel\u2019s safety profile is not as well established. In such scenarios, the risks and benefits should be weighed carefully, often involving a multidisciplinary discussion. Option a (DAPT) is correct because the SAMMPRIS trial demonstrated that using both aspirin and clopidogrel reduces recurrent stroke risk in severe intracranial stenosis. Other alternatives like single antiplatelet therapy, anticoagulation, or immediate endovascular procedures have either not shown superior benefits or carry higher procedural risks. 1. The SAMMPRIS trial firmly supports DAPT in the acute management of symptomatic high-grade intracranial stenosis. 2. Aggressive medical management and risk factor modification remain the cornerstone of therapy. 3. Noninvasive imaging is key to an accurate diagnosis and subsequent management planning. Recent guidelines continue to reinforce that for symptomatic intracranial atherosclerotic disease, DAPT for a period (commonly 90 days) along with intensive risk factor management is the optimal first-line approach. Endovascular intervention is reserved for selected cases when medical management fails.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with ESRD Scenario with pic showing rt superficial borderzone infarction at MCA/ACA territory asking about next investigation",
    "option_a": "(Brain CTA) is acceptable as the next investigation if it includes imaging of the neck vessels. It is noninvasive and provides reliable information about both intracranial and extracranial vessels. Option b (Conventional angiography) is more invasive and carries a higher risk of complications including stroke, arterial injury, and contrast nephropathy, particularly in ESRD; hence, it is reserved for cases where noninvasive tests are inconclusive or for planning interventional procedures.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In patients with watershed (borderzone) infarcts, it is important to evaluate the entire cerebrovascular axis as these infarcts can be related to either hemodynamic compromise or proximal large vessel disease. Noninvasive vascular imaging is pivotal in clarifying the cause. Borderzone or watershed infarcts occur at the junctions between vascular territories, often due to hypoperfusion or embolic events affecting both intracranial and extracranial vessels. In patients with ESRD, who may have vascular calcifications and concomitant atherosclerosis, assessing both extra- and intracranial vasculature is crucial. In the setting of ESRD and borderzone infarcts, the patient may have subtle neurological deficits. Given the association with renal disease, there is often extensive vascular disease, making comprehensive vascular imaging essential for further management. A CT angiography (CTA) that ideally includes both the intracranial and neck vessels is preferred. Although the option provided mentions brain CTA (which might imply that neck vessels are included as per standard protocol), it is critical to assess for extracranial carotid stenosis as well. Differential diagnoses include embolic stroke from a cardiac source, vasculitis, or internal carotid occlusion. Once vascular imaging is performed, management involves addressing underlying etiologies. First-line investigations include noninvasive CTA (with both brain and neck imaging) due to its rapidity and lower risk. In patients with ESRD, contrast administration must be judicious; however, in those on dialysis the risk of further renal injury is less of a concern. In scenarios involving pregnancy, alternative imaging modalities or minimized contrast protocols should be considered to reduce fetal exposure. Option a (Brain CTA) is acceptable as the next investigation if it includes imaging of the neck vessels. It is noninvasive and provides reliable information about both intracranial and extracranial vessels. Option b (Conventional angiography) is more invasive and carries a higher risk of complications including stroke, arterial injury, and contrast nephropathy, particularly in ESRD; hence, it is reserved for cases where noninvasive tests are inconclusive or for planning interventional procedures. 1. Watershed infarcts should prompt a full evaluation of both intra- and extracranial vasculature. 2. In ESRD patients, the use of CTA remains acceptable due to the limited concern over contrast-induced nephropathy in end-stage disease. 3. Noninvasive imaging is the preferred first step in vascular evaluation. Recent studies endorse the use of comprehensive CTA as an effective, rapid, and safe tool for evaluating patients with suspected cerebrovascular disease. In patients with ESRD, modifications in contrast use are considered, but the overall imaging strategy remains the same.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Minor stroke NIHSS 3 (left side decrease sensation, mild facial weakness) within the window what\u2019s next",
    "option_a": "(DAPT) is incorrect as sole acute treatment because while it reduces recurrent events, it does not actively lyse the clot. Option b (tPA) is correct because clot dissolution is essential for reperfusion in the hyperacute phase of ischemic stroke. Option c (Aspirin alone) is insufficient for acute reperfusion therapy; it is used more for secondary prevention post",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "For patients presenting with a minor stroke (NIHSS 3) within the treatment window, the crucial decision is whether to use IV thrombolysis to restore perfusion. Even minor deficits can be disabling, and timely reperfusion is key. Ischemic stroke results from occlusion of cerebral arteries, leading to infarction of brain tissue downstream. Thrombolytic therapy with tPA initiates enzymatic fibrinolysis of the clot, thereby restoring blood flow and potentially minimizing infarct size if administered early in the time window. Patients with minor stroke symptoms, like decreased sensation and mild facial weakness, may still experience significant disability. Early intervention with IV tPA can improve outcomes by re-establishing perfusion before irreversible damage ensues. The diagnosis of an ischemic stroke is primarily based on clinical assessment and neuroimaging (typically noncontrast CT) to rule out hemorrhage. Differential diagnoses include transient ischemic attack (TIA), migraine with aura, or seizure-related deficits, but imaging along with clinical findings usually clarifies the diagnosis. For eligible patients presenting within 4.5 hours from symptom onset, IV thrombolysis with tPA is considered first-line therapy. Although DAPT (aspirin plus clopidogrel) has proven benefits in secondary prevention (as per the CHANCE and POINT trials), it does not have the reperfusion action required in the hyperacute phase. In the context of pregnancy or lactation, the use of tPA demands a rigorous risk-benefit assessment. Although tPA is not an absolute contraindication during pregnancy, caution is advised due to the potential risk of maternal and fetal hemorrhage; multidisciplinary consultation is recommended. Option a (DAPT) is incorrect as sole acute treatment because while it reduces recurrent events, it does not actively lyse the clot. Option b (tPA) is correct because clot dissolution is essential for reperfusion in the hyperacute phase of ischemic stroke. Option c (Aspirin alone) is insufficient for acute reperfusion therapy; it is used more for secondary prevention post-thrombolysis or when tPA is contraindicated. 1. Even minor strokes with low NIHSS scores can be disabling; timely tPA administration is crucial. 2. The therapeutic time window for tPA is 4.5 hours from symptom onset. 3. DAPT is useful for secondary prevention, not as a replacement for acute thrombolytic therapy. Recent guidelines from the American Heart Association/American Stroke Association continue to recommend IV tPA within the 4.5-hour window for eligible patients, even for minor strokes if deficits are considered disabling. Multiple trials have consolidated the role of thrombolysis in acute management over antiplatelet-only strategies.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "82 female with stroke NIHSS 20, BP 180/100, 3 hrs from symptoms onset, brain CT pic look okay no clear hypodensity but showed subtle early ischemic changes in BG, insular ribbon what to do next",
    "option_a": "(Labetalol) is incorrect because the patient\u2019s blood pressure is already below the threshold that would mandate reduction prior to thrombolysis. Option b (Thrombolysis) is correct because the patient is within the therapeutic window and meets criteria for acute reperfusion therapy. Option c (Thrombectomy) is not the immediate next step without vascular imaging confirmation of a large vessel occlusion and is typically adjunctive to tPA rather than a substitute in this scenario.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case involves an elderly patient with a significant acute ischemic stroke (NIHSS 20) who is still within the 4.5-hour window for reperfusion therapy. The priority is to restore cerebral blood flow quickly, provided that contraindications, such as uncontrolled high blood pressure, are not present. Acute ischemic stroke results from a sudden reduction in blood flow, leading to infarction. Intravenous thrombolysis with tissue plasminogen activator (tPA) acts by cleaving plasminogen into plasmin, which dissolves the thrombus. Despite subtle early CT changes (e.g., insular ribbon, basal ganglia hypodensity), these findings do not preclude tPA use if they do not involve a large area of established infarction. The patient\u2019s high NIHSS score indicates a severe stroke, and the presentation is consistent with a large vessel occlusion or a severe cortical/subcortical infarct. Although the blood pressure is 180/100 mmHg, it is below the threshold of >185/110 mmHg that typically necessitates aggressive antihypertensive management before thrombolysis. A noncontrast CT scan is used primarily to exclude hemorrhage and to identify early signs of ischemia. The decision for reperfusion therapy is based on clinical assessment, timing, and imaging. Differential diagnoses include stroke mimics such as seizure postictal states, hypoglycemia, or intracranial hemorrhage, but these are ruled out by the scan and clinical context. For patients within the 4.5-hour window, IV thrombolysis with tPA is the first-line therapy. Blood pressure management is essential only if values exceed 185/110 mmHg. Since this patient\u2019s BP is 180/100 mmHg, there is no need for pre-thrombolytic antihypertensive therapy. Mechanical thrombectomy may be considered subsequently if large vessel occlusion is confirmed, but the immediate priority is IV tPA. In pregnant or lactating patients, the use of tPA is a challenging decision; although not an absolute contraindication, careful assessment by a multidisciplinary team is essential to balance maternal benefits versus risks to the fetus. Option a (Labetalol) is incorrect because the patient\u2019s blood pressure is already below the threshold that would mandate reduction prior to thrombolysis. Option b (Thrombolysis) is correct because the patient is within the therapeutic window and meets criteria for acute reperfusion therapy. Option c (Thrombectomy) is not the immediate next step without vascular imaging confirmation of a large vessel occlusion and is typically adjunctive to tPA rather than a substitute in this scenario. 1. For tPA eligibility, the blood pressure must be <185/110 mmHg; values slightly below this threshold do not require pre-treatment antihypertensives. 2. Early ischemic changes on CT do not automatically exclude patients from thrombolysis. 3. In high NIHSS strokes, prompt reperfusion therapy is crucial to salvage penumbral tissue. Contemporary guidelines from AHA/ASA continue to support IV thrombolysis with tPA within 4.5 hours of symptom onset in eligible patients. Recent studies emphasize that strict blood pressure management prior to tPA is warranted only when levels exceed the set threshold, reinforcing that timely reperfusion is the critical factor in improving outcomes.",
    "exam_year": "2022",
    "exam_type": "Part I",
    "image_url": "page_23.png"
  },
  {
    "question": "Acute stroke treated with tPA pic showing tongue angio edema, patient stable but severely dysarthric, what to do",
    "option_a": "(Intubation) is inappropriate because the patient is currently stable without airway compromise\u2014intubation is indicated only when there is imminent respiratory failure or severe obstruction. Option B (Steroid with antihistamine) directly addresses the inflammatory and mediator",
    "option_b": "",
    "option_c": "(ACE inhibitor with diuretics) is contraindicated because ACE inhibitors can exacerbate angioedema by further increasing bradykinin levels, and diuretics do not address the underlying issue and may worsen hemodynamics.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "tPA-induced angioedema is a recognized complication of thrombolytic therapy. It is thought to be mediated by an increase in bradykinin levels that causes vasodilation and increased vascular permeability, resulting in localized swelling\u2014often seen in the tongue or facial area. tPA catalyzes the conversion of plasminogen to plasmin, which not only dissolves clots but can also lead to increased bradykinin production. Elevated bradykinin levels cause vascular leakage leading to angioedema. Patients with a history of ACE inhibitor use are at an increased risk, though it can occur independently. The underlying mechanism involves an atypical inflammatory response that is not IgE-mediated. In this patient, although there is severe dysarthria (likely from tongue swelling affecting articulation), the airway remains uncompromised. Recognizing that the patient is stable without respiratory distress guides management away from invasive airway protection unless further compromise occurs. The diagnosis is primarily clinical with a correlation between recent tPA administration and the onset of localized swelling. Differential diagnoses include allergic reactions, anaphylaxis, or other causes of upper airway edema. However, the timing post-tPA and the focal nature (tongue angioedema) supports the diagnosis of tPA-induced angioedema. First-line treatment in tPA-induced angioedema is medical management using steroids (e.g., methylprednisolone) and antihistamines (e.g., diphenhydramine) to reduce inflammation and counter any histamine-mediated effects. Airway management (e.g., intubation) is reserved for cases with evidence of respiratory compromise or rapidly progressing edema. In pregnant or lactating patients, steroids and antihistamines are used when benefits outweigh risks; close monitoring of both mother and fetus is essential, and consultation with maternal\u2013fetal medicine is advised in severe cases. Option A (Intubation) is inappropriate because the patient is currently stable without airway compromise\u2014intubation is indicated only when there is imminent respiratory failure or severe obstruction. Option B (Steroid with antihistamine) directly addresses the inflammatory and mediator-driven process, making it the correct initial management. Option C (ACE inhibitor with diuretics) is contraindicated because ACE inhibitors can exacerbate angioedema by further increasing bradykinin levels, and diuretics do not address the underlying issue and may worsen hemodynamics. 1. Always assess for airway compromise in patients with angioedema\u2014if the airway is stable, medical management is preferred. 2. tPA-induced angioedema is bradykinin-mediated, so typical anaphylaxis protocols (epinephrine) may not be effective. 3. History of concomitant ACE inhibitor use can increase the risk of this complication. Recent stroke management guidelines acknowledge tPA-induced angioedema as a rare complication and recommend early medical management with steroids and antihistamines. Studies emphasize that prompt recognition and treatment can prevent progression to airway obstruction, reducing the overall morbidity associated with thrombolytic therapy.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "TIA found to have atrial flutter echo normal",
    "option_a": "(Factor Xa inhibitor) is correct as these agents have been shown to reduce the risk of cardioembolic stroke effectively. The marked answer was B, which is incorrect. Other potential options might include antiplatelet therapy or solely using rate",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Transient Ischemic Attacks (TIAs) associated with atrial flutter are typically the result of cardioembolic events. In nonvalvular atrial flutter, thrombus formation within the atria can lead to embolization and subsequent neurological deficits. Atrial flutter results in rapid, regular atrial contractions that foster blood stasis, particularly in the atrial appendage, thereby increasing the risk of thrombus formation. These emboli may dislodge and travel to cerebral vasculature causing TIAs or strokes. Although the echocardiogram is normal (suggesting no structural heart disease), the arrhythmia itself remains the source of embolism. A patient with atrial flutter and TIA is at significant risk for future strokes of embolic origin. Recognizing the cardioembolic mechanism is essential for instituting appropriate long\u2010term anticoagulation to prevent recurrence. Diagnosis is confirmed through ECG demonstrating atrial flutter. Echocardiography is used to rule out structural abnormalities but does not exclude the risk posed by the arrhythmia. Differential diagnoses include TIAs from large artery atherosclerosis or small vessel disease, which typically have different risk profiles and management strategies. The latest guidelines recommend the use of direct oral anticoagulants (DOACs), particularly Factor Xa inhibitors (e.g., apixaban, rivaroxaban), as first-line therapy for stroke prevention in patients with nonvalvular atrial flutter and atrial fibrillation. In the acute setting following a TIA, early initiation of appropriate anticoagulation is indicated. For pregnant patients, however, DOACs are contraindicated due to teratogenicity and limited safety data; low molecular weight heparin (LMWH) is preferred in such cases. Similar caution applies during lactation, with LMWH being considered safer. Option A (Factor Xa inhibitor) is correct as these agents have been shown to reduce the risk of cardioembolic stroke effectively. The marked answer was B, which is incorrect. Other potential options might include antiplatelet therapy or solely using rate-control medications, but these do not address the embolic risk adequately. 1. Atrial flutter and fibrillation both confer a high risk for cardioembolic events, necessitating prompt anticoagulation. 2. Echocardiography may be normal in these patients despite significant embolic risk. 3. Factor Xa inhibitors are favored in the nonpregnant population for their ease of use and favorable risk\u2013benefit profile. Recent trials and updates in cardiology guidelines support DOACs\u2014including Factor Xa inhibitors\u2014as first-line agents for stroke prevention in nonvalvular atrial arrhythmias. Ongoing research continues to compare outcomes between DOACs and warfarin, firmly establishing the DOAC class as a mainstay in this field.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "Case of malignant MCA with mass effect and decreased level of consciousness found unresponsive, what will change outcomes",
    "option_a": "(Decompressive hemicraniectomy) directly addresses the life\u2010threatening cerebral edema and mass effect, thereby altering the natural history and improving survival and functional outcome. Option B (Stroke admission) is an important supportive measure but does not counteract the mass effect. Option C (Hyperventilation) may transiently reduce ICP via cerebral vasoconstriction but is not a definitive treatment, and its effects are short",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Malignant middle cerebral artery (MCA) infarction is a severe form of ischemic stroke characterized by extensive cerebral edema and mass effect, often leading to rapid neurological deterioration and death if left untreated. A large MCA infarct results in cytotoxic and vasogenic edema that significantly increases intracranial pressure (ICP). This swelling can lead to herniation syndromes, which are life-threatening. Decompressive hemicraniectomy is performed to alleviate the pressure, thereby reducing the risk of secondary brain injury. Patients typically present with decreased level of consciousness, hemiparesis, and signs of raised ICP. The rapid deterioration seen in malignant MCA infarcts correlates with the underlying pathophysiology of uncontrollable edema and midline shift. Diagnosis is confirmed via neuroimaging such as CT or MRI, which shows a large infarct territory, midline shift, and signs of herniation. Differential diagnoses include intracerebral hemorrhage and cerebral venous thrombosis; however, the imaging characteristics and clinical setting help distinguish malignant MCA infarction. The first-line treatment to change outcomes in malignant MCA infarction is decompressive hemicraniectomy, ideally performed within 24\u201348 hours of symptom onset, as multiple randomized controlled trials have demonstrated improved survival and functional outcomes. Supportive care in a specialized stroke unit is essential but not sufficient as a standalone intervention. In pregnant patients, decompressive surgery may still be indicated when maternal life is at risk; multidisciplinary management involving neurosurgery, obstetrics, and neonatology is critical. In lactating mothers, the surgical decision-making remains similar with additional supportive measures. Option A (Decompressive hemicraniectomy) directly addresses the life\u2010threatening cerebral edema and mass effect, thereby altering the natural history and improving survival and functional outcome. Option B (Stroke admission) is an important supportive measure but does not counteract the mass effect. Option C (Hyperventilation) may transiently reduce ICP via cerebral vasoconstriction but is not a definitive treatment, and its effects are short-lived. The marked answer was D, which does not correspond to any effective intervention for altering outcomes in malignant MCA infarction. 1. Timely decompressive hemicraniectomy can significantly reduce mortality in malignant MCA infarction. 2. Recognize that supportive care alone (stroke unit admission) is not sufficient in the face of malignant edema. 3. Temporary measures like hyperventilation are only bridges to definitive therapy. Landmark studies such as DESTINY, DECIMAL, and HAMLET have confirmed the benefit of early decompressive hemicraniectomy in selected patients with malignant MCA infarction. These studies have influenced current guidelines, emphasizing surgery within 48 hours as a key determinant of improved outcome.",
    "exam_year": "2022",
    "exam_type": "Part I"
  },
  {
    "question": "SCA came with ??",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "1",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Stroke involving the territory of the Superior Cerebellar Artery (SCA) can affect lateral midbrain and cerebellar structures. The involvement of descending sympathetic fibers leads to the development of ipsilateral Horner's syndrome, manifesting as ptosis, miosis, and anhidrosis. The SCA supplies parts of the lateral midbrain and upper cerebellum. Ischemia in this region may disrupt sympathetic pathways that run adjacent to these structures, thereby causing ipsilateral Horner's syndrome. The disruption is due to infarction of small fibers that regulate sympathetic outflow. Patients with SCA stroke may present with cerebellar signs such as ataxia along with additional features like ipsilateral Horner's syndrome. Recognition of these signs assists in localizing the lesion to the lateral midbrain and SCA territory. Neuroimaging including MRI and CT angiography are used to delineate the affected vascular territory. The differential diagnosis includes lateral medullary (Wallenberg) syndrome, midbrain infarcts from other arterial distributions, and other brainstem pathologies. Isolated 4th nerve palsies usually point to lesions in the dorsal midbrain, which are less typical in SCA infarcts. Management of SCA infarcts is largely supportive and similar to other ischemic strokes with antithrombotic therapy initiation, risk factor modification, and rehabilitation. In the acute setting, if the patient is within the thrombolytic window and meets criteria, IV thrombolysis may be considered. In pregnant or lactating patients, the risk\u2013benefit analysis of thrombolytic therapy is performed on a case-by-case basis, with current guidelines advising cautious use when indicated. Option 1 (Ipsilateral Horner's syndrome) is correct because it is a classic clinical finding that results from involvement of sympathetic fibers in the lateral midbrain adjacent to the SCA territory. Option 2 (4th cranial nerve palsy) is incorrect, as isolated trochlear nerve involvement is uncommon in SCA infarcts and usually suggests a different midbrain lesion location. 1. Ipsilateral Horner's syndrome is a key lateralizing sign in strokes involving the lateral midbrain or upper brainstem. 2. Recognize that posterior circulation strokes have unique clinical syndromes compared to anterior circulation strokes. 3. Detailed neuro-ophthalmologic examination can significantly aid in lesion localization. Recent reviews of posterior circulation stroke syndromes consolidate the finding that sympathetic pathway involvement, leading to ipsilateral Horner's syndrome, is a reliable clinical sign in SCA territory infarcts. Advanced imaging techniques continue to refine our understanding of the vascular territories involved in brainstem strokes.",
    "exam_year": "2022",
    "exam_type": "Part I"
  }
]